Nucleus of the cardiometabolic-exposures cluster. WHO 2012, all recommendations strong.
The word conditional does not appear in the document.
The recommendations
“WHO recommends a reduction in sodium intake to reduce blood pressure and risk of cardiovascular disease, stroke and coronary heart disease in adults (strong recommendation). WHO recommends a reduction to <2 g/day sodium (5 g/day salt) in adults (strong recommendation).” [EXTRACTED (WHO - Sodium Intake 2012) Recommendations, p.18]
For children: reduce to control blood pressure (strong), with the adult 2 g/day figure “adjusted downward based on the energy requirements of children relative to those of adults” — a scaling rule, with no outcome evidence and no certainty rating attached to it.
No certainty rating is attached to any recommendation line — certainty lives only in the per-outcome tables and an Annex 8 bullet list.
The narrow, checked contrast with a later WHO guideline. WHO’s 2023 SFA/TFA guideline uses the
same bare “(strong recommendation)” form on its recommendation lines — there is no
(strong recommendation, moderate-certainty evidence) pairing in it, zero occurrences. What SFA 2023
does add is an overall certainty stated per recommendation in its Rationale (“The overall
certainty in the evidence for recommendation 1 was moderate, and for recommendation 2 was very low”);
this 2012 guideline issues no overall certainty anywhere.
[EXTRACTED (WHO - Saturated and Trans Fatty Acid Intake 2023) Recommendations; Rationale — a
cross-guideline check, so cited here in body rather than added to this page’s sources:]
The evidence split — this is the whole story
| Outcome | Effect (95% CI) | Design | Certainty |
|---|---|---|---|
| Resting SBP | 3.39 mmHg lower (2.46 to 4.31) | 36 RCTs, 49 comparisons, n=6736 | HIGH |
| Resting DBP | 1.54 mmHg lower (0.98 to 2.11) | 36 RCTs | HIGH |
| Ambulatory SBP | 5.51 mmHg lower (3.16 to 7.87) | 6 studies | HIGH |
| All-cause mortality | RR 1.06 (0.94 to 1.20) — inconclusive | 7 cohorts, n=21 515 | VERY LOW |
| Stroke | RR 1.24 (1.08 to 1.43) | 10 cohorts, n=72 878 | VERY LOW |
| Cardiovascular disease | RR 1.12 (0.93 to 1.34) — inconclusive | 9 cohorts, n=46 483 | VERY LOW |
| Coronary heart disease | RR 1.04 (0.86 to 1.24) — inconclusive | 6 cohorts, n=37 343 | VERY LOW |
| Cardiovascular disease | RR 0.84 (0.57 to 1.23) — inconclusive | 2 RCTs, n=720 | MODERATE |
[EXTRACTED (WHO - Sodium Intake 2012) Summary of evidence, pp.11-13; Annex 1]
The surrogate is rated HIGH; most — not all — hard cohort outcomes are rated VERY LOW. The exception matters and the table above omitted it: fatal stroke, RR 1.63 (1.27-2.10), is rated LOW, and fatal coronary heart disease, RR 1.32 (1.13-1.53), is the other statistically significant cohort result. Both were left out while the four null rows were listed — an omission running in the direction of the “surrogate high, hard outcomes very low” reading, which is exactly the direction such omissions tend to run. WHO’s own summary states the split: “Higher sodium intake was associated with higher risk of incident stroke, fatal stroke and fatal coronary heart disease. There was no association between sodium intake and all-cause mortality, incident cardiovascular disease and non-fatal coronary heart disease.” [EXTRACTED (WHO - Sodium Intake 2012) Executive summary; Summary of evidence]
But note the last row: a 2-RCT meta-analysis of cardiovascular disease is rated moderate — direct hard-outcome RCT evidence, above the cohort floor, though its interval is wide and null. WHO summarizes the split itself:
“The evidence regarding the relationship between sodium intake and blood pressure was of high quality, whereas the evidence regarding sodium intake and all-cause mortality, cardiovascular disease, stroke and coronary heart disease was of lower quality. Therefore, these recommendations should be reviewed when more evidence… becomes available.” [EXTRACTED (WHO - Sodium Intake 2012) Remarks, p.18]
How the gap is bridged — a disclosed surrogate transfer
The bridge is explicit, and it is the guideline’s most consequential methodological act:
“Because of the well-established relationship between blood pressure and cardiovascular disease outcomes, the evidence of an effect of sodium on blood pressure was also considered moderate-quality evidence that reduced sodium is beneficial for reducing risk of cardiovascular disease, stroke and coronary heart disease.” [EXTRACTED (WHO - Sodium Intake 2012) Annex 8, p.37]
High-certainty surrogate evidence is transferred to hard outcomes one level down, and the direct very-low-certainty cohort evidence on those same outcomes is superseded rather than combined. There is no stated roll-up rule anywhere in the document — the string “overall certainty” does not occur, and no overall certainty is ever issued. The transfer rule in Annex 8 is the operative substitute.
Where this bites hardest — the <2 g/day threshold. The evidence table for that specific question carries four rows reading “There were no studies with [cardiovascular disease / stroke / coronary heart disease / all cause mortality] as an outcome which addressed this question”, each labelled (directly assessed). Annex 8 nonetheless states:
“High and moderate-quality evidence that consuming <2 g sodium/day compared with consuming >=2 g sodium/day is beneficial for reducing blood pressure and risk of cardiovascular disease, stroke and coronary heart disease in adults.” [EXTRACTED (WHO - Sodium Intake 2012) Annex 1 p.24; Annex 8 p.37]
This is not a contradiction, and “no studies” does not mean “no evidence.” Two qualifiers do the work, and both are printed on the cell itself:
- the rows say (directly assessed), and
- footnote 2 hangs off those very cells: “Though the effect of a decrease in sodium intake was not
tested, there were 5 cohort studies that compared lower sodium intake (<2g/day) to higher sodium
intake (>= 2 g/day). There was a significant increased risk of stroke in the group that consumed
=2 g/day relative to the group that consumed < 2 g/day (RR=1.30 (1.03 to 1.64)). Effects on the risk of cardiovascular disease, coronary heart disease and all cause mortality were not statistically significant.”
[EXTRACTED (WHO - Sodium Intake 2012) Annex 1 p.24, footnote 2]
So the threshold claim rests on high-certainty BP evidence at that threshold, transferred at moderate, plus 5 indirect cohort comparisons showing a stroke effect. What is absent is a directly assessed trial of the threshold against a hard outcome — which is a narrower and more accurate statement than “zero evidence.” [INFERRED (WHO - Sodium Intake 2012) — entailment from the annexes and the cell footnote read together.]
Response heterogeneity — measured, then deliberately not acted on
| Baseline status | SBP reduction (95% CI) | Certainty |
|---|---|---|
| Hypertensive | 4.06 mmHg (2.96 to 5.15), 24 studies | high |
| Mixed | 3.41 mmHg (1.69 to 5.13), 8 studies | high |
| Normotensive | 1.38 mmHg (0.02 to 2.74), 6 studies | moderate |
A roughly three-fold difference, which WHO records as “statistically significantly less” in normotensives — and then declines to stratify the recommendation, on a stated population-level ground: the high global prevalence of hypertension and the breadth of benefit. The reason given is a public-health-standpoint reason, not an evidentiary one (telos divergence class 1). [EXTRACTED (WHO - Sodium Intake 2012) Final considerations, p.16]
By baseline intake, point estimates rise monotonically with intake (1.79 -> 2.97 -> 3.07 -> 3.91 -> 5.74 mmHg across intake bands) and WHO reads the subgroup test as null (P=0.17), concluding the effect is “independent of baseline sodium intake.” A monotone gradient declared absent on a non-significant interaction test is a claim about power as much as about biology. [INFERRED (WHO - Sodium Intake 2012) — entailment from the reported estimates and the stated P value.]
The J-curve — named as the reason for the review, then never adjudicated
WHO names the J-shaped hypothesis twice in framing sections, citing two 2011 cohort studies proposing that reducing sodium below 2 g/day “may be associated with increased risk of cardiovascular disease and stroke” as part of the justification for commissioning the review. Neither study is returned to anywhere in the evidence summary, the final considerations, or the annexes, and whether they were among the 15 included cohorts is not stated. The terms reverse causation, sick-quitter and U-shaped do not appear in the document. [EXTRACTED (WHO - Sodium Intake 2012) Background p.6; Justification p.7]
Compounding this: the strata where a lower-arm harm is most plausible were excluded a priori — “individuals with illnesses or taking drug therapy that may lead to hyponatraemia… (e.g. patients with heart failure and those with type I diabetes)… were not considered in the review of the evidence.” [EXTRACTED (WHO - Sodium Intake 2012) Remarks, p.18]
So the guideline cannot answer the J-curve question, and does not claim to. Per the expectancy test
this is unprobed, not disproved — and it is the wiki’s largest open question on sodium.
AWAITS a source that adjudicates the upper-arm/lower-arm question directly (the post-2011 literature:
PURE, the Cochrane and Graudal lines, and the reviews rebutting them).
What is absent
- Absolute effects entirely. No per-1000, no risk differences, no baseline risk, no NNT. The mmHg figures are absolute in units but never translated to outcome risk. So this recommendation cannot be ranked against any other exposure in the fabric (telos layer 1).
- A numeric “threshold of relevance” — the criterion driving every imprecision downgrade is defined only qualitatively and never operationalized for any outcome.
- Salt sensitivity / hyperresponders — the terms do not occur. The hypertensive/normotensive split above is the closest the document comes.
- Sodium:potassium ratio — explicitly out of scope, while asserting that following this guideline plus the potassium guideline yields “approximately one to one, which is considered beneficial for health”, sourced to a 2003 expert consultation rather than to evidence graded here.
- Any low- or middle-income-country evidence. All RCTs were run in Australia, Europe, North America and New Zealand; cohorts in Europe, Japan and the USA. The PICO setting is “All countries” and transportability is never discussed — while the guideline’s stated motivation is LMIC-framed.
Limits
- 2012; self-dated for review “by the end of 2017”. The post-2011 sodium controversy is by construction outside it.
- Three of the four underpinning systematic reviews are unpublished WHO in-house documents with no journal or URL, so study lists, risk-of-bias assessments and heterogeneity statistics are not verifiable from this document alone.
- The guideline’s evidence-state vocabulary has three states (conclusive-of-benefit/harm, conclusive-of-no-effect, inconclusive) and the middle one requires the threshold it never specifies. WHO does exercise the conclusive-of-no-effect state — the tempting reading that it never does is wrong: total cholesterol and plasma noradrenaline are rated high and explicitly “did not cross threshold of relevance of benefit or harm”, with Annex 8 carrying “High-quality evidence that decreasing sodium has no harmful effect on blood lipids, catecholamine levels, renal function or any minor side effects (e.g. headache and dizziness) in adults.” It is used on the adverse-effect outcomes, and scoped to adults. What the guideline does not do is apply it to the efficacy outcomes — those stay “inconclusive” in the body and reappear as “no association” in the Executive summary, which is the four-states error the telos names.
The exposure measure here is in a different class from the rest of the corpus [2026-07-28, Willett ch.8]
Almost every dietary exposure the wiki holds is measured by food-frequency questionnaire. Sodium is not. Van Dam & Hunter classify urinary sodium as a recovery biomarker — one of only four they name, alongside urinary nitrogen, urinary potassium and doubly-labelled-water energy:
«In addition to urinary nitrogen, urinary potassium, urinary sodium, and energy intake estimated using the doubly labeled water technique are recovery biomarkers.» [EXTRACTED (Willett - Nutritional Epidemiology 3e) chunk 09]
A recovery biomarker has «a quantitative relationship… between values for the biomarker and dietary intake in a specific time period», so it yields absolute intake rather than a ranking. Full taxonomy and its consequences: Measurement Error in Dietary Assessment.
What this does and does not buy.
- It removes one error source, not the others. Design, confounding and outcome ascertainment are untouched. This page’s certainty split — high on blood pressure, very low on hard outcomes — is unaffected, and nothing here upgrades it.
- It does not solve day-to-day variation. A 24-hour urine measures one day, and a single day is a poor estimate of habitual intake for any nutrient. Recovery fixes calibration; it does not fix within-person variability, and the two are independent problems.
- What it does buy is that a sodium threshold is auditable in a way most are not. Chapter 4’s
division — questionnaires for ranking, records or recalls for absolute magnitude when «comparing
nutrient intakes with specific dietary recommendations» — is the general obstacle to checking a
person against a cutpoint. Sodium escapes it, because an absolute intake can be measured
directly. WHO’s «<2 g/day sodium» is therefore one of the few guidance numbers in this corpus a
person could actually be measured against.
[INFERRED (Willett - Nutritional Epidemiology 3e; WHO - Sodium Intake 2012) — the classification is Van Dam & Hunter's and the threshold is WHO's; the auditability consequence is this page's]
A second guidance family on the same stratification — and it is NOT a second witness [2026-07-28, ESC]
ESC - CVD Prevention Guidelines 2021 reports the same hypertensive/normotensive split this page already holds from WHO:
«A reduction in sodium intake may reduce SBP by, on average, 5.8 mmHg in hypertensive, and 1.9 mmHg in normotensive patients.» [EXTRACTED (ESC - CVD Prevention Guidelines 2021) chunk 04]
Parameter table (op-weave 2a) — built because the surface agreement is striking:
| Parameter | WHO 2012 | ESC 2021 | Same quantity? |
|---|---|---|---|
| Hypertensive SBP reduction | 4.06 mmHg (2.96-5.15), 24 studies | 5.8 mmHg | NO — ESC states no dose |
| Normotensive SBP reduction | 1.38 mmHg (0.02-2.74), 6 studies | 1.9 mmHg | NO — same reason |
| Ratio hypertensive : normotensive | 2.94 | 3.05 | comparable — both are internal ratios, so the missing dose cancels |
| Sodium reduction assumed | specified in WHO’s analysis | not stated in this sentence | — |
| Uncertainty | intervals given | none given | no |
The magnitudes are not comparable and the ratio is. ESC’s sentence attaches no dose, so its 5.8 and 1.9 cannot be set against WHO’s 4.06 and 1.38 — a larger assumed reduction would produce larger numbers with no disagreement at all. What survives the dose problem is the internal ratio, because the unstated dose divides out of it: 2.94 against 3.05. Two guidance families, a decade apart, on a roughly 3:1 hypertensive-to-normotensive gradient.
That agreement is NOT independent backing, and the check is what shows it
Both trace to the same investigators. ESC’s cited source for this sentence is He FJ, Tan M, Ma Y, MacGregor GA (JACC 2020), and He FJ / MacGregor GA studies sit inside WHO’s own included-studies list. So the convergence runs through one research group’s primary work reaching two guideline committees.
No [E-independent] is claimable here. Every surface marker points the wrong way — different body,
different continent, different decade, near-identical ratio — and the substantive marker is absent.
This is the laundering trap in its textbook form, and it was caught by checking the reference rather
than by the numbers looking suspicious.
[INFERRED (ESC - CVD Prevention Guidelines 2021; WHO - Sodium Intake 2012) — the figures are each body's; the shared-lineage finding is this page's]
Stated at the width the evidence supports: what is established is shared primary-study lineage, not that the two pooled estimates were computed from identical study sets. The wiki has not established that, and the differing magnitudes suggest they were not.
What ESC adds that WHO does not have
- A hard-outcome magnitude for a stated dose: «In a meta-analysis, salt reduction of 2.5 g/day resulted in a 20% reduction of ASCVD events (RR 0.80).» This page’s central gap is that hard outcomes sit at very low certainty, and ESC supplies a figure — but from the same He/MacGregor source, so it does not raise certainty, and ESC attaches no certainty rating to it.
- The gap between intake and target, quantified: «In most Western countries, salt intake is high (9-10 g/day), whereas the recommended maximum intake is 5 g/day.» A halving, population-wide — which is an adherence fact, not an efficacy one, and belongs in any realistic reading of what the recommendation asks. [EXTRACTED (ESC - CVD Prevention Guidelines 2021) chunk 04]
A blood-pressure number is not a blood-pressure number [2026-07-28, ESC chunk 05]
This page’s outcome is SBP, and it already carries a puzzle: WHO’s pooled resting SBP effect is 3.39 mmHg while its ambulatory SBP effect is 5.51 mmHg — the ambulatory figure is larger than the resting one, on the same exposure. ESC supplies the mechanism.
White-coat hypertension is common and carries intermediate risk:
«It occurs in up to 30-40% of patients. The risk associated with white-coat hyperten- sion is lower than sustained hypertension but may be higher than normotension.» [EXTRACTED (ESC - CVD Prevention Guidelines 2021) chunk 05]
So office/resting measurement misclassifies a large minority, in a direction that adds variance
uncorrelated with the exposure. An intervention effect measured against a noisier, upward-contaminated
baseline attenuates, which is the expected direction of the WHO resting-vs-ambulatory gap.
[INFERRED (ESC - CVD Prevention Guidelines 2021; WHO - Sodium Intake 2012) — the white-coat prevalence and risk gradient are ESC's, the two SBP figures are WHO's; the attenuation reading is this page's]
ESC applies a measurement correction to SPRINT’s headline number
«the even lower SBP in the intensively treated group in SPRINT (Systolic Blood Pressure Intervention Trial) (mean 124 mmHg) probably reflects a conventional office SBP range of 130-139 mmHg» [EXTRACTED (ESC - CVD Prevention Guidelines 2021) chunk 05]
A landmark trial’s most-quoted number is restated as 130-139 in the units a clinic actually uses — a shift of roughly 6-15 mmHg, larger than the entire sodium effect this page reports. The trial is not wrong; the number is method-specific, and reading it against a conventional office reading is a same-quantity error of the exact kind the parameter-table rule exists to catch.
The consequence for this page, stated at the right width: any BP figure — WHO’s 3.39, ESC’s 5.8/1.9, a personal reading — carries an implicit measurement method, and the methods are not interchangeable. This does not impeach any figure held here. It means a threshold and a measured value must share a method before they can be compared, and none of the sources this page holds states its method in the same breath as its number.
AWAITS a source specifying the BP measurement protocol behind WHO’s pooled estimates — that is
what would let this page say whether its central figure is an office, resting-standardised or
ambulatory quantity. The wiki cannot currently say which.